These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35431057)

  • 41. Medical treatment of advanced cutaneous squamous-cell carcinoma.
    Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
    Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
    Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
    Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
    Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD
    Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055
    [No Abstract]   [Full Text] [Related]  

  • 45. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Hernández-Guerrero T; Doger B; Moreno V
    Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
    Giri A; Bauman JR
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience.
    Hasmat S; Howle JR; Carlino MS; Sundaresan P; Veness MJ
    ANZ J Surg; 2023 Jan; 93(1-2):235-241. PubMed ID: 36567642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
    Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
    Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
    McLean LS; Lim AM; Bressel M; Lee J; Ladwa R; Guminski AD; Hughes B; Bowyer S; Briscoe K; Harris S; Kukard C; Zielinski R; Alamgeer M; Carlino M; Mo J; Park JJ; Khattak MA; Day F; Rischin D
    Med J Aust; 2024 Feb; 220(2):80-90. PubMed ID: 38212673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
    Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
    JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab).
    Challapalli A; Stewart G; Shaw H; Davies PJ; Lopez-Baez JC; Ottley EC; Kelly S
    Front Immunol; 2024; 15():1408667. PubMed ID: 39072317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center.
    Denaro N; Passoni E; Indini A; Nazzaro G; Beltramini GA; Benzecry V; Colombo G; Cauchi C; Solinas C; Scartozzi M; Marzano AV; Garrone O
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies.
    Lang R; Welponer T; Richtig E; Wolf I; Hoeller C; Hafner C; Nguyen VA; Kofler J; Barta M; Koelblinger P; Hitzl W; Emberger M; Laimer M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1799-1810. PubMed ID: 37210651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
    Stevenson ML; Wang CQ; Abikhair M; Roudiani N; Felsen D; Krueger JG; Pavlick AC; Carucci JA
    JAMA Dermatol; 2017 Apr; 153(4):299-303. PubMed ID: 28259107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.
    Yang F; Paccaly AJ; Rippley RK; Davis JD; DiCioccio AT
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):479-494. PubMed ID: 33728546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment approaches of advanced cutaneous squamous cell carcinoma.
    Peris K; Piccerillo A; Del Regno L; Di Stefani A
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():19-22. PubMed ID: 34855254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
    Mager L; Gardeen S; Carr DR; Shahwan KT
    Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.
    Joseph K; Walker J; Raziee H; Faruqi S; Smylie M
    J Cutan Med Surg; 2022; 26(3):243-248. PubMed ID: 34866423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.
    Buquicchio R; Mastrandrea V; Strippoli S; Quaresmini D; Guida M; Filotico R
    Front Oncol; 2021; 11():691980. PubMed ID: 34540666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.